18
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
UCSF Benioff Children's Hospital Oakland, Oakland
University of Massachusetts Medical School, Worcester
University of Massachusetts, Worcester
OTHER
UCSF Benioff Children's Hospital Oakland
OTHER